Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reaching consensus in relapsed/refractory ALL in AYAs.

Blood advances·2026
Same author

Economic burden associated with switching from frontline pegaspargase or calaspargase pegol to second-line recombinant <i>Erwinia</i> in pediatrics and adolescents/young adults with acute lymphoblastic leukemia.

Journal of medical economics·2026
Same author

Toxicity from asparaginase during acute lymphoblastic leukemia induction: A report from the Children's Oncology Group.

Blood advances·2026
Same author

Adding induction intrathecal cytarabine in newly diagnosed CNS2 B-acute lymphoblastic leukemia does not improve outcomes.

Blood advances·2026
Same author

Chromosome 15q deletions confer inferior outcomes among children with ETV6::RUNX1 B-cell acute lymphoblastic leukemia.

Blood advances·2026
Same author

Erratum: Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025
Same journal

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best practice & research. Clinical haematology·2025
Same journal

Immune therapy of haematological cancers.

Best practice & research. Clinical haematology·2025
Same journal

Advances in NK cell therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Adoptive cellular therapies in multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Bispecific T-cell engager therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
See all related articles

Related Experiment Video

Updated: Jan 3, 2026

A Protocol for Phage Display and Affinity Selection Using Recombinant Protein Baits
12:36

A Protocol for Phage Display and Affinity Selection Using Recombinant Protein Baits

Published on: February 16, 2014

34.9K

Can Ph-like ALL be effectively targeted?

Luke Maese1, Elizabeth A Raetz2

  • 1Department of Pediatrics and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

Best Practice & Research. Clinical Haematology
|November 30, 2019
PubMed
Summary
This summary is machine-generated.

Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk B-cell ALL subset impacting adolescents and young adults. Targeted therapies and immunotherapy are being investigated due to poor prognosis with standard chemotherapy.

Keywords:
ALLAcute lymphoblastic leukemiaCRLF2Cytokine receptor-like factor 2DasatinibPh-like ALLPhiladelphia chromosome-likeRuxolitinibTKITyrosine kinase inhibitor

More Related Videos

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein
11:23

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein

Published on: June 30, 2019

6.6K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.4K

Related Experiment Videos

Last Updated: Jan 3, 2026

A Protocol for Phage Display and Affinity Selection Using Recombinant Protein Baits
12:36

A Protocol for Phage Display and Affinity Selection Using Recombinant Protein Baits

Published on: February 16, 2014

34.9K
Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein
11:23

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein

Published on: June 30, 2019

6.6K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.4K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) represents a high-risk subtype of B-cell ALL.
  • This subtype is characterized by genetic alterations activating kinase or cytokine receptor signaling pathways.
  • Ph-like ALL is prevalent in adolescents and young adults, contributing to poorer outcomes in this demographic.

Purpose of the Study:

  • To investigate the characteristics and treatment landscape of Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL).
  • To highlight the challenges posed by Ph-like ALL to conventional chemotherapy regimens.
  • To underscore the exploration of novel therapeutic strategies, including targeted therapies and immunotherapy, for Ph-like ALL.

Main Methods:

  • Review of existing literature on Ph-like ALL genetics and clinical outcomes.
  • Analysis of current clinical trials investigating targeted agents and immunotherapy for Ph-like ALL.
  • Examination of the biological diversity within the Ph-like ALL subgroup.

Main Results:

  • Ph-like ALL exhibits diverse genetic drivers impacting signaling pathways.
  • Conventional chemotherapy shows limited efficacy, leading to inferior prognoses.
  • Ongoing trials are evaluating molecularly targeted therapies and immunotherapy.

Conclusions:

  • Ph-like ALL is a distinct, high-risk leukemia subtype requiring novel treatment approaches.
  • Targeted therapies and immunotherapy show promise for improving outcomes in Ph-like ALL patients.
  • Further research is crucial to understand and leverage the biological diversity of Ph-like ALL for effective treatment.